Nicotine Rewires Habenular Circuits in Mice, Altering Food Motivation

The Enduring Neural Footprint of Tobacco Use

Tobacco use disorder remains a leading cause of preventable mortality, yet achieving long-term abstinence is notoriously difficult even with established pharmacotherapies. A meta-analysis of 10,110 patients demonstrates that varenicline yields a significantly higher continuous abstinence rate at 12 weeks compared to bupropion (odds ratio 1.79, 95% confidence interval 1.59 to 2.02, p < 0.001) [1]. This clinical challenge is compounded because nicotine dependence co-occurs in 33.4% to 65% of patients with severe mental illness [2] and physically alters brain architecture. Magnetic resonance imaging (MRI) data from nearly 3,000 individuals reveals decreased gray matter volume in the right anterior cingulate and altered intrinsic function within the default mode and salience networks (interconnected brain regions that govern self-reflection and the ability to focus on relevant stimuli) [3]. While researchers are currently conducting nine clinical trials to test whether glucagon-like peptide 1 receptor agonists, such as semaglutide, can curb nicotine cravings [4], clinicians must also navigate concurrent substance use. Data from 229,630 patients shows that cannabis co-use lowers the odds of successful tobacco cessation by 35% (odds ratio 0.65, p < 0.0001) [5]. A recent study now offers fresh insights into how chronic nicotine exposure physically rewires deep brain circuitry to alter baseline motivation for natural rewards, providing specific neurobiological targets to help improve future cessation therapies.

Mapping the Nicotine-Exposed Brain

To understand how tobacco dependence reshapes the brain, researchers investigated circuit alterations that parallel drug-related behaviors beyond standard drug-seeking mechanisms. The study utilized an animal model where male mice were chronically exposed to nicotine in their drinking water for 6 weeks, simulating the sustained systemic exposure seen in human tobacco use. Following this chronic exposure phase, the researchers combined behavioral measures in operant and non-operant tasks (tests that assess how hard an animal will work for a reward versus its spontaneous behavior) to evaluate changes in baseline motivation. This approach allowed the investigators to isolate how nicotine alters the drive for natural rewards, such as food, independent of the direct craving for the drug itself.

To map the underlying neurobiology driving these motivational shifts, the investigators deployed a suite of advanced laboratory techniques. The researchers combined patch clamp with optogenetics and in vivo electrophysiological recordings to provide a comprehensive cellular analysis of nicotine's impact on living brain tissue. Patch clamp techniques measure the electrical properties of individual neurons, while optogenetics uses light to control specific, genetically modified cells, allowing the team to pinpoint exactly which neural circuits were misfiring. Furthermore, these functional assessments were paralleled with high-resolution array tomography to monitor structural adaptations. By utilizing array tomography (an imaging technique that reconstructs three-dimensional tissue structures from ultrathin slices), the team could visualize the physical synaptic changes caused by chronic nicotine exposure. For clinicians, these microscopic structural changes help explain why the behavioral patterns of addiction persist long after the physical withdrawal symptoms have resolved.

Dysregulation of the Reward Circuitry

Clinicians have long observed that tobacco use significantly impacts reward-driven behavior, leading to comorbidities across a lifetime, including metabolic syndrome and concurrent psychiatric disorders. To understand the cellular basis of these lifelong clinical challenges, the researchers examined the ventral tegmental area (VTA), a deep brain structure central to dopamine production and reward processing. The study revealed that chronic nicotine dampened the cholinergic modulation of VTA dopamine neuron activity. Cholinergic modulation refers to the regulatory input from acetylcholine-producing neurons that normally fine-tunes dopamine release. By blunting this regulatory signal, prolonged nicotine exposure fundamentally alters how the brain's reward center responds to everyday stimuli.

This physiological blunting translates directly into observable behavioral shifts. The researchers demonstrated that the dampening of cholinergic modulation in the VTA led to an exaggerated motivation for food reward seeking. In a clinical context, this mechanism helps explain why patients with tobacco use disorder often experience intense cravings for highly palatable foods or struggle with weight management during cessation attempts. The investigators mapped this behavioral shift to a specific neural pathway, concluding that chronic nicotine consumption alters motivation for natural rewards by disrupting top-down control of the lateral habenula (LHb) onto the laterodorsal tegmentum (LDT) and VTA cholinergic axis. The LHb typically acts as an anti-reward center that signals disappointment and suppresses dopamine release. By disrupting the signals from the LHb to the LDT and subsequently to the VTA, nicotine effectively removes the brain's natural brakes on reward-seeking behavior, leaving patients vulnerable to compulsive consumption of non-drug rewards.

Restoring Motivational Control via Chemogenetics

To prove that these specific neural pathways drive the observed behavioral changes, the study utilized chemogenetics to selectively modulate cholinergic inputs to the ventral tegmental area (VTA). Chemogenetics is a laboratory technique where engineered receptors are introduced into specific neurons so they can be precisely turned on or off by administering a targeted drug. By applying this method, the researchers achieved bidirectional control over the animals' behavior. They found that selective chemogenetic enhancement of cholinergic tone from the laterodorsal tegmentum (LDT) to the VTA restored normal motivational control in the nicotine-exposed mice. Conversely, silencing the cholinergic projection from the LDT to the VTA triggered the opposite effect, worsening motivational control and further exaggerating the drive for food rewards.

Looking deeper at the cellular level, the study revealed structural and functional deficits in the synaptic integration of excitatory inputs from the lateral habenula (LHb) onto LDT cholinergic neurons projecting to the VTA. Synaptic integration refers to the process by which a neuron combines multiple incoming electrical signals to determine whether it will fire and pass the message along. Because nicotine damages this integration process, the inhibitory signals from the LHb fail to properly reach the reward centers. The investigators confirmed that the structural and functional deficits in the LHb to LDT-VTA circuit correlate with the observed behavioral alterations. For clinicians treating tobacco dependence, these results provide a concrete biological mechanism for why patients often struggle with mood and motivation during cessation. The findings highlight previously unrecognized cellular and synaptic contributors to nicotine's impact on mental health, demonstrating that chronic tobacco use physically degrades the microscopic connections required for normal reward processing and emotional regulation.

References

1. Patel A, Panchal J, Desai CK. Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Psychiatry. 2023. doi:10.4103/indianjpsychiatry.indianjpsychiatry_218_22

2. Fornaro M, Carvalho AF, Prisco MD, et al. The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis.. Neuroscience and biobehavioral reviews. 2022. doi:10.1016/j.neubiorev.2021.11.039

3. Ma L, Tao Q, Dang J, et al. The structural and functional brain alternations in tobacco use disorder: a systematic review and meta-analysis.. Frontiers in psychiatry. 2025. doi:10.3389/fpsyt.2025.1403604

4. Patil S, Jha N, Jha MK. Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.. Addictive behaviors reports. 2026. doi:10.1016/j.abrep.2026.100671

5. Costa GPA, Gómez O, Cerezo-Matias MA, Funaro MC, Sofuoglu M, Aquino JPD. Cannabis Co-Use and Endocannabinoid System Modulation in Tobacco Use Disorder: A Translational Systematic Review and Meta-Analysis.. medRxiv : the preprint server for health sciences. 2026. doi:10.64898/2026.02.12.26346166